BNT327 Optimized Dose

Phase 2Small molecule

BNT327 Optimized Dose is one of 25 small molecule programs targeting Extensive-stage Small-cell Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Extensive-Stage Small-Cell Lung CancerActive, not recruiting

Locally Advanced Breast CancerActive, not recruiting

Extensive-Stage Small-Cell Lung CancerPhase 2

Active, not recruiting

Locally Advanced Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Extensive-Stage Small-Cell Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Phase 3

7 2

Beyfortus

BeiGene

Phase 3

2 3

Vepesid

AAvyxa

Phase 3

10 4

Paraplatin

AAvyxa

Phase 3

9 5

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

5 6

Pumitamig

Bristol-Myers Squibb

Phase 3

1 7

Imfinzi

AstraZeneca

Phase 2

4 8

Tarlatamab-Dznl

Amgen

Phase 2

3 9

BL-B01D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

2 10

QL2107

Qilu Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Extensive-Stage Small-Cell Lung Cancer

NCT06449209

Q2 2029

Phase 2Active, not recruiting

Locally Advanced Breast Cancer

NCT06449222

Clinical

Trials by Indication[1]

Extensive-stage Small-cell Lung Cancer1 trial

A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449209·110 enrolled

Locally Advanced Breast Cancer1 trial

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Active, not recruiting· BioNTech logo

BioNTech·Phase 2·NCT06449222·83 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BNT327 Optimized Dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT327 Optimized Dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT327 Optimized Dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: BioNTech

BNT327 Optimized Dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q2 2029

Trials by Indication[1]

Extensive-stage Small-cell Lung Cancer1 trial

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News